Chasing rapid weight loss with trendy injections now comes with a new concern: a rare but alarming threat to eyesight.
Medications like Ozempic were first embraced as game‑changers for diabetes and obesity. Now, fresh research is raising questions about how these drugs might affect the delicate blood supply to the eye, with a handful of patients experiencing abrupt and sometimes permanent vision loss.
From diabetes drug to weight-loss craze
Semaglutide, sold under the brand names Ozempic, Wegovy and Rybelsus, was originally designed to treat type 2 diabetes. It mimics a hormone called GLP‑1, which boosts insulin release, lowers blood sugar and slows digestion.
Patients often feel full sooner and eat less. Many lose a substantial amount of weight, alongside improvements in blood pressure, cholesterol and other markers linked to heart disease.
That mix of medical benefit and dramatic weight shifts has turned semaglutide into a social media phenomenon. Celebrities, influencers and ordinary users share before‑and‑after photos, and waiting lists for prescriptions have grown in several countries.
Behind the hype, specialists are now scrutinising a potential price: a small increase in the risk of sudden, irreversible vision loss.
A rare condition nicknamed a “stroke of the eye”
The main concern centres on a condition called non‑arteritic anterior ischaemic optic neuropathy, or NAION. Ophthalmologists sometimes refer to it as a “stroke of the eye”.
NAION happens when the blood supply to the optic nerve head drops sharply. That nerve carries visual signals from the eye to the brain. When it is damaged, part of the field of vision can disappear within hours.
- Onset is usually painless.
- People may wake up with a blurry patch or a dark area in one eye.
- Vision loss often stabilises after a short time, but lost sight usually does not return.
The condition is rare, affecting only a few people in every 100,000 each year. Age over 50, diabetes, high blood pressure, sleep apnoea and certain anatomical features of the optic nerve all increase risk.
European regulators added NAION to the list of very rare side effects for semaglutide in 2025, after reviewing reported cases. They advised patients and doctors to stop treatment at once if sudden visual changes appear.
➡️ The Norwegian army managed to seize control of a bomb dropped mid‑flight by a US fighter jet
➡️ 12 things flight attendants notice about you the moment you board
➡️ What it means when someone avoids eye contact in conversation, according to psychology
➡️ The subtle symptoms of liver cancer to watch for before it’s too late, according to experts
➡️ Major breakthrough: the world’s longest venomous snake is actually four distinct species
➡️ This simple trick helps you stop forgetting important small tasks
➡️ This supermarket butter under €4 is rated the best of all by 60 Millions de consommateurs
What the new studies actually show
The Massachusetts Eye and Ear Hospital analysis
One of the most closely watched pieces of research came from Massachusetts Eye and Ear Hospital, which examined data from 2017 to 2023. The team followed more than 16,000 adults with diabetes or obesity, some of whom were prescribed semaglutide and some who were not.
The researchers reported their findings in JAMA Ophthalmology in 2024. They found that NAION appeared more often in patients taking semaglutide than in those on other treatments.
| Patient group | Relative NAION risk with semaglutide |
|---|---|
| With type 2 diabetes | About 4 times higher |
| With obesity (no diabetes) | More than 7 times higher |
The drug did not cause NAION in most users. The absolute number of cases remained low, but the difference between groups caught attention.
The study does not prove that semaglutide directly damages the optic nerve, yet the strength and consistency of the signal have triggered serious debate among clinicians.
International data point in the same direction
A separate project led by researchers at the Karolinska Institutet in Sweden and the University of Melbourne added more nuance. Tracking a large group of patients on GLP‑1 drugs, including semaglutide, they calculated that about 0.04% developed NAION during follow‑up.
This rate was still very low but slightly higher than in comparable people not taking the drugs. The team stressed that diabetes itself raises the risk of NAION, echoing older research, including a 2013 meta‑analysis that found a roughly 64% increase in risk linked to diabetes alone.
That overlap complicates interpretation. Are GLP‑1 drugs raising risk on top of diabetes, or are they simply used more often in people who were already vulnerable?
Balancing benefits and eye risks
For doctors, the question is not whether Ozempic “is safe” or “is dangerous” in absolute terms. The calculation is more personal: does this individual patient gain more from weight loss and better diabetes control than they risk from a very rare eye event?
For many, the answer is still yes. Semaglutide helps lower the chances of heart attacks, strokes and deaths related to cardiovascular disease. Those outcomes are far more common than NAION.
Yet some people need closer attention:
- Patients with a history of optic nerve disease or unexplained vision loss
- Those with severe sleep apnoea, longstanding high blood pressure or uncontrolled diabetes
- People with a “crowded” optic disc (a particular optic nerve shape seen on eye examination)
In these groups, many ophthalmologists now recommend baseline eye checks before starting GLP‑1 therapy, followed by regular monitoring.
Specialists emphasise one practical step: any sudden change in vision while on these drugs should be treated as an emergency, not something to “watch and wait”.
What patients on Ozempic and similar drugs can do
People already taking semaglutide do not need to panic or stop their medication on their own. Abruptly quitting can spike blood sugar and lead to rapid weight regain, both of which pose real health risks.
Instead, clinicians suggest a few concrete habits:
- Know the warning signs: a shadow, curtain or blurry patch in one eye, particularly on waking.
- Seek urgent care: contact an emergency eye service or A&E if those signs appear.
- Tell your eye doctor: mention any GLP‑1 drugs at every ophthalmology appointment.
- Manage basics: control blood pressure, blood sugar and sleep apnoea, which all affect eye circulation.
If a patient with suspected NAION is on semaglutide, guidelines from European regulators advise stopping the drug and discussing alternative treatments with an endocrinologist or obesity specialist.
Why the optic nerve might be vulnerable
Scientists are still piecing together how GLP‑1 drugs could influence the optic nerve. Several ideas are being studied:
- Rapid swings in blood sugar may affect tiny blood vessels feeding the nerve.
- Changes in blood pressure during sleep could temporarily lower blood flow.
- Direct effects of GLP‑1 receptors in the eye’s own tissues are not fully understood.
A long‑term trial now under way is following about 1,500 patients for five years. Researchers will track detailed images of the retina and optic nerve, hoping to spot early micro‑changes before symptoms arise.
Key terms patients often ask about
Many people encountering this issue for the first time find the jargon confusing. Two phrases come up repeatedly.
GLP‑1 receptor agonist: This is the drug class that includes semaglutide. “Agonist” here just means a compound that activates a receptor. These medicines signal the body in a way similar to a natural hormone, guiding insulin release and appetite.
NAION: Non‑arteritic anterior ischaemic optic neuropathy refers to damage to the front part of the optic nerve from reduced blood flow that is not caused by inflammation or a blocked artery. The condition usually affects one eye at a time and tends to occur in people with vascular risk factors.
Real‑life scenarios and trade‑offs
Imagine a 58‑year‑old with type 2 diabetes, obesity and a history of a mild heart attack. For this person, semaglutide might lower the chance of another cardiac event, support weight loss and stabilise blood sugar. Their absolute risk of NAION remains small, even if it is slightly higher on the drug.
Now picture a 55‑year‑old with severe sleep apnoea, very high blood pressure and a “crowded” optic disc in both eyes. They may already sit close to the threshold at which blood flow to the optic nerve becomes precarious during the night. In that case, a shared decision with both an endocrinologist and an ophthalmologist makes sense, weighing weight‑loss needs against a potentially heightened eye risk.
These situations show why blanket statements about Ozempic and vision can mislead. The same drug that changes one person’s life for the better may carry a more complicated risk profile for another. What remains consistent is the value of early symptom reporting, honest discussion with clinicians and careful monitoring of both metabolic health and sight.
Originally posted 2026-02-06 17:12:15.